Gilead’s First-In-Class Drug For Aggressive Breast Cancer On Track For EU Approval
Conditional Approval In Store For Janssen’s Non-Small Cell Lung Cancer Treatment
EU reviewers have recommended five new medicines and a pneumococcal vaccine for EU-wide approval. New uses of several approved medicines have also drawn the thumbs up, while the sponsor of a cancer drug has withdrawn its product from the review process.
You may also be interested in...
The European Medicines Agency is this week due to decide whether to back pan-EU marketing authorization for five new medicines, including a combination antibiotic product and a drug for chemotherapy-induced neutropenia.
The Pink Sheet's EU accelerated assessment tracker has been updated to include developments relating to investigational products from, among others, Janssen, Sanofi, Boehringer Ingelheim and Mirum.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.